About Xcovery
Xcovery is a company based in West Palm Beach (United States) founded in 2006. It operates as a Professional Services. Xcovery has raised $37.52 million across 7 funding rounds. The company has 18 employees as of December 31, 2023. Xcovery offers products and services including Ensacove™ (Ensartinib) and Vorolanib. Xcovery operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter West Palm Beach, United States
- Employees 18 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37.52 M (USD)
in 7 rounds
-
Latest Funding Round
$675 K (USD), Series B
May 08, 2015
-
Investors
Not available
-
Employee Count
18
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xcovery
Xcovery offers a comprehensive portfolio of products and services, including Ensacove™ (Ensartinib) and Vorolanib.
Ensartinib is approved for ALK-driven cancer treatment.
Vorolanib inhibits angiogenesis in various cancer treatments.
People of Xcovery
Unlock access to complete
Funding Insights of Xcovery
Xcovery has successfully raised a total of $37.52M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $675 thousand completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Xcovery
Investment portfolio details for Xcovery
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xcovery
Detailed financials for Xcovery
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xcovery Comparisons
Peer comparison for Xcovery
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xcovery
Xcovery operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Xcovery
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xcovery
Complete news archive for Xcovery
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xcovery
Xcovery was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Xcovery is headquartered in West Palm Beach, United States. It is registered at West Palm Beach, Florida, United States.
Xcovery is a funded company, having raised a total of $37.52M across 7 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Xcovery is 18.
Xcovery is engaged in the development of advanced oncology therapies aimed at improving outcomes for patients with cancer. The company is dedicated to creating treatments that are more effective and less toxic than existing options. Key products include Ensacove (Ensartinib), an FDA-approved ALK inhibitor for non-small cell lung cancer, and Vorolanib, a multikinase angiogenesis inhibitor for various tumor types. Partnerships and investments are sought to expand the reach and development of these therapies globally within the healthcare sector.
Xcovery's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Xcovery offers Ensacove™ (Ensartinib) and Vorolanib.